![common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]](https://revolutionhealth.org/cdn/shop/articles/GLP-1_comparison_for_weight_loss.png?v=1769219496)
common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]
Description
[DOI] [PMC free article] [PubMed] [Google Scholar] 27.Adriaenssens A, Broichhagen J, de Bray A, Ast J, Hasib A, Jones B, et al
![common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/glp1.png?w=600&tok=baf39c)
95% CI, 0.23-0.38).2 Additionally, teclistamab reduced the risk of death by 40% compared with SOC treatment (HR, 0.60
![common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]](https://www.news-medical.net/images/news/ImageForNews_789910_1725921735019553.jpg)
It works by decreasing appetite and cravings
![common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]](https://medrac.web.unc.edu/wp-content/uploads/sites/22579/2025/03/AD_4nXecYXk7BfwC6adHH808V596nosg2pYs4yDUs6TBM_JMmx7_pGkjqpOwyHWy2Rj2TdJt-SPUxEipYqiO5CftWX-CaAm_fXRTU6dpEuJkuUscaLenZ1xGLWDdf_XVsOIjaZt08BpA4A.png)
Keywords: glucagon-like peptide-1 receptor, cinchonine, drug repurposing, non-alcoholic steatohepatitis, type 2 diabetes mellitus Graphical Abstract: Introduction Diabetes is a major threat to human health worldwide
![common glp 1 agonists GLP-1 Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat Revolution Health & Wellness glp-1_analogs [TUSOM | Pharmwiki]](https://b1167102.smushcdn.com/1167102/wp-content/uploads/2025/07/GLP01.jpg?lossy=2&strip=1&webp=1)
